Citi upgrades Arcturus Therapeutics to Buy, lifts price target to $20
on improved ARCT-810, ARCT-2601 OTC prospects
- Citi moved rating to Buy from Neutral and raised its Arcturus price target to $20 from $8.
- Citi cited improved prospects for ARCT-810 and ARCT-2601 in ornithine transcarbamylase (OTC) deficiency.
- Arcturus signed a definitive agreement to acquire computational biology firm myNEO to bolster AI-driven mRNA design and target identification capabilities.
- Arcturus reported encouraging interim Phase 2 results for ARCT-810 in OTC deficiency.
- Favorable FDA feedback allows next-generation LUNAR 2.0 candidate ARCT-2601 to join the ongoing ARCT-810 study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.